Wall Street analysts expect that Kura Oncology, Inc. (NASDAQ:KURA) will report ($0.41) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kura Oncology’s earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.49). Kura Oncology reported earnings of ($0.37) per share in the same quarter last year, which would indicate a negative year over year growth rate of 10.8%. The firm is scheduled to issue its next earnings results on Monday, November 6th.
On average, analysts expect that Kura Oncology will report full-year earnings of ($1.64) per share for the current fiscal year, with EPS estimates ranging from ($1.82) to ($1.45). For the next fiscal year, analysts expect that the business will report earnings of ($2.20) per share, with EPS estimates ranging from ($2.70) to ($1.69). Zacks’ EPS averages are an average based on a survey of analysts that follow Kura Oncology.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03.
Several brokerages have recently weighed in on KURA. ValuEngine cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research cut Kura Oncology from a “buy” rating to a “hold” rating in a report on Wednesday. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $16.00 price objective on shares of Kura Oncology in a report on Tuesday, July 4th. Leerink Swann reiterated an “outperform” rating and issued a $18.00 price objective (up from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. Finally, Cowen and Company started coverage on Kura Oncology in a report on Thursday. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $14.15.
Shares of Kura Oncology (NASDAQ:KURA) opened at 11.80 on Thursday. Kura Oncology has a one year low of $4.00 and a one year high of $13.80. The stock’s market capitalization is $235.86 million. The stock has a 50 day moving average price of $7.97 and a 200 day moving average price of $8.71.
ILLEGAL ACTIVITY WARNING: “Brokerages Anticipate Kura Oncology, Inc. (KURA) to Announce -$0.41 Earnings Per Share” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/09/10/brokerages-anticipate-kura-oncology-inc-kura-to-announce-0-41-earnings-per-share.html.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board acquired a new position in Kura Oncology in the second quarter valued at approximately $102,000. Oppenheimer & Co. Inc. lifted its holdings in Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock valued at $110,000 after acquiring an additional 1,600 shares during the last quarter. Segantii Capital Management Ltd acquired a new position in Kura Oncology in the first quarter valued at approximately $120,000. Rhumbline Advisers acquired a new position in Kura Oncology in the second quarter valued at approximately $131,000. Finally, Nationwide Fund Advisors acquired a new position in Kura Oncology in the first quarter valued at approximately $136,000. Hedge funds and other institutional investors own 39.07% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.